Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations.
Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations.
复制标题
DOI：
10.1016/j.amjcard.2008.02.031
复制
发表时间：
2008-04
期刊：
影响因子：
--
通讯作者：
A. Scanu;Ravinder Bamba
中科院分区：
文献类型：
--
作者：
A. Scanu;Ravinder Bamba
多年来，烟酸已被公认为动脉粥样硬化保护剂，部分原因是其能够降低胆固醇、甘油三酯和极低密度脂蛋白和低密度脂蛋白的血浆水平，并显著升高高密度脂蛋白。在高剂量下，烟酸也被报道降低脂蛋白（a）（Lp[a]）的血浆水平。然而，已发表的关于该主题的研究在患者选择、药物剂量、给药时间长度和血浆Lp（a）定量方法方面缺乏统一性。在这份报告中，作者检查了最相关的烟酸相关Lp（a）研究和假设的药物作用机制，还考虑了Lp（a）作为潜在促炎实体的新概念。
Over the years, niacin has gained recognition as an atheroprotective agent, in part because of its capacity to lower the plasma levels of cholesterol, triglycerides, and very-low- and low-density lipoproteins and to substantially raise high-density lipoprotein. In high doses, niacin has also been reported to lower the plasma level of lipoprotein(a) (Lp[a]). However, the published research on the subject suffers from a lack of uniformity regarding patient selection, drug dose, length of administration, and methods for plasma Lp(a) quantification. In this report, the authors examine the most relevant niacin-related Lp(a) studies and hypothetical mechanisms of drug action, also considering the emerging notion of Lp(a) as a potential proinflammatory entity.